Literature DB >> 17082613

CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma.

Ori Wald1, Uzi Izhar, Gail Amir, Shani Avniel, Yochai Bar-Shavit, Hanna Wald, Ido D Weiss, Eithan Galun, Amnon Peled.   

Abstract

The chemokine receptor CXCR4 is involved in the growth and metastasis of tumor cells. However, the expression of its ligand, the chemokine CXCL12, in tumors and its role in regulating the accumulation of immune cells within the tumors is not clear. Using ELISA and immunohistochemistry we found that CXCL12 is expressed in the majority of nonsmall cell lung cancer tissue sections obtained from stage IA to IIB nonsmall cell lung cancer patients undergoing operation. Histopathologic examination of these sections indicated that high CXCL12 expression correlated with increased tumor inflammation. In addition, disease recurrence rates in a subgroup of adenocarcinoma patients showed a tendency to correlate with high CXCL12 expression in the tumor. Isolation of adenocarcinoma-infiltrating immune cells demonstrated an increase in the percentage of CD4+CD69+CXCR4+ T cells as compared with normal lung tissue. About 30% of these cells expressed the regulatory T cell markers CD25high and FoxP3. The percentage of CD8 T cells within the tumor did not change, however; the percentage of NK and NK T cells was significantly reduced. In correlation with CXCR4 expression, CD4 T cells showed increased migration in response to CXCL12 compared with CD8 T cells and NK cells. Overall, these observations suggest that CXCL12 expression may influence tumor progression by shaping the immune cell population infiltrating lung adenocarcinoma tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082613     DOI: 10.4049/jimmunol.177.10.6983

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.

Authors:  Sophie Kirshberg; Uzi Izhar; Gail Amir; Jonathan Demma; Fiona Vernea; Katia Beider; Zippora Shlomai; Hanna Wald; Gideon Zamir; Oz M Shapira; Amnon Peled; Ori Wald
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

Review 2.  Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas.

Authors:  Shisuo Du; Mary Helen Barcellos-Hoff
Journal:  Semin Radiat Oncol       Date:  2013-10       Impact factor: 5.934

3.  Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer.

Authors:  H Imai; N Sunaga; Y Shimizu; S Kakegawa; K Shimizu; T Sano; T Ishizuka; T Oyama; R Saito; J D Minna; M Mori
Journal:  Int J Immunopathol Pharmacol       Date:  2010 Jan-Mar       Impact factor: 3.219

Review 4.  Phenotypical and functional specialization of FOXP3+ regulatory T cells.

Authors:  Daniel J Campbell; Meghan A Koch
Journal:  Nat Rev Immunol       Date:  2011-02       Impact factor: 53.106

Review 5.  The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.

Authors:  Andreas Bikfalvi; Clotilde Billottet
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

Review 6.  Once a Treg, always a Treg?

Authors:  Deepali V Sawant; Dario A A Vignali
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

7.  Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer.

Authors:  B Weixler; F Renetseder; I Facile; N Tosti; E Cremonesi; A Tampakis; T Delko; S Eppenberger-Castori; A Tzankov; G Iezzi; C Kettelhack; S D Soysal; U von Holzen; G C Spagnoli; L Terracciano; L Tornillo; Raoul A Droeser; S Däster
Journal:  Cell Oncol (Dordr)       Date:  2017-09-21       Impact factor: 6.730

8.  Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases.

Authors:  Margaret Gil; Mukund Seshadri; Marcin P Komorowski; Scott I Abrams; Danuta Kozbor
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

9.  Polymeric Plerixafor: effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection.

Authors:  Yan Wang; Jing Li; David Oupický
Journal:  Pharm Res       Date:  2014-06-19       Impact factor: 4.200

10.  Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients.

Authors:  Frank M Speetjens; Gerrit Jan Liefers; Cornelis J Korbee; Wilma E Mesker; Cornelis J H van de Velde; Ronald L van Vlierberghe; Hans Morreau; Rob A Tollenaar; Peter J K Kuppen
Journal:  Cancer Microenviron       Date:  2008-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.